QCG
TVTX icon

Quadrant Capital Group’s Travere Therapeutics TVTX Stock Holding History

Quadrant Capital Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305K Hold
5,367
– – 0.01% 1076
2026
Q1 		$159K Sell
5,367
-883
-14% -$26.4K ﹤0.01% 1337
2025
Q4 		$239K Sell
6,250
-372
-6% -$12.1K 0.01% 1240
2025
Q3 		$158K Buy
+6,622
New +$124K 0.01% 1337
2025
Q2 		– Sell
-6,724
Closed -$120K – 2536
2025
Q1 		$120K Buy
6,724
+102
+2% +$2.07K ﹤0.01% 1483
2024
Q4 		$115K Hold
6,622
– – 0.01% 985
2024
Q3 		$92.6K Hold
6,622
– – 0.01% 1111
2024
Q2 		$54.4K Buy
6,622
+4,554
+220% +$30.7K ﹤0.01% 1362
2024
Q1 		$15.9K Sell
2,068
-391
-16% -$3.3K ﹤0.01% 1937
2023
Q4 		$22.1K Buy
2,459
+2,419
+6,048% +$17.6K ﹤0.01% 1772
2023
Q3 		$358 Buy
+40
New +$564 ﹤0.01% 2618
2023
Q2 		– Sell
-41
Closed -$923 – 2777
2023
Q1 		$923 Buy
+41
New +$872 ﹤0.01% 2547
2021
Q4 		– Sell
-41
Closed -$1K – 2699
2021
Q3 		$1K Buy
+41
New +$753 ﹤0.01% 2399

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's TVTX Position: Q2 2026 in Review

Quadrant Capital Group held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 5,367 shares worth $305K. The position accounts for 0.01% of the portfolio, ranked #1076.

Quadrant Capital Group first reported a position in TVTX in Q3 2021 and has held it in 13 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Quadrant Capital Group held 5,367 shares of Travere Therapeutics worth $305K as of Q2 2026.
  • Quadrant Capital Group left its Travere Therapeutics share count unchanged in Q2 2026.
  • Travere Therapeutics made up 0.01% of Quadrant Capital Group's portfolio in Q2 2026, its #1076 holding.
  • Quadrant Capital Group first reported a position in Travere Therapeutics in Q3 2021 and has held it in 13 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.